A5091348562- Cutaneous Melanoma Detection and Management
- Virus-based gene therapy research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Melanoma and MAPK Pathways
- Herpesvirus Infections and Treatments
- Nonmelanoma Skin Cancer Studies
- Optical Coherence Tomography Applications
- Insect and Pesticide Research
- Dermatology and Skin Diseases
- Vector-Borne Animal Diseases
- Central Venous Catheters and Hemodialysis
- Allergic Rhinitis and Sensitization
- AI in cancer detection
- Monoclonal and Polyclonal Antibodies Research
- Venous Thromboembolism Diagnosis and Management
- Acupuncture Treatment Research Studies
- Poxvirus research and outbreaks
- Vascular Procedures and Complications
- Complementary and Alternative Medicine Studies
- Cancer Immunotherapy and Biomarkers
The Netherlands Cancer Institute
2017-2023
Society of Surgical Oncology
2019-2022
Amsterdam UMC Location University of Amsterdam
2016
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1), which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%. Since December 2016, 48 eligible started treatment at the Netherlands Cancer Institute. We included 26 this follow up time ≥6 months, reporting Overall Response Rate (ORR), Disease Control (DCR), Adverse Events...
Promising technology
Abstract Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients melanoma have shown high clinical and pathologic response rates. Treatment talimogene laherparepvec (T-VEC), a modified herpes simplex virus type-1 (HSV-1), is approved for unresectable stage IIIB-IVM1a has the potential to make tumors more susceptible ICI. Combination ICI intralesional T-VEC already been investigated IIIB-IV disease, however, no data available yet on benefit of...
Abstract Background Patients with melanoma and negative sentinel nodes (SNs) have varying outcomes, dependent on several prognostic factors. Considering all these factors in a prediction model might aid identifying patients who could benefit from personalized treatment strategy. The objective was to construct validate nomogram for recurrence melanoma-specific mortality (MSM) SNs. Methods A total of 3220 SNs were identified cohort 4124 four EORTC Melanoma Group centres underwent lymph node...
Now effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize its risk/benefit ratio is crucial. The American Joint Committee on Cancer system the most widely used validated melanoma system, which recently released 8th edition. We aimed externally validate prognostic discriminatory ability for survival of edition compared 7th evaluate factors. Prospective database stage III (2000-2016). Prognostic factors melanoma-specific distant metastasis-free...
9546 Background: Neoadjuvant systemic treatment with checkpoint inhibitors (ICI) has shown high response rates in patients resectable metastasized melanoma. In unresectable stage IIIB-IVA melanoma, intralesional talimogene laherparepvec (T-VEC) also and durable rates. this trial we investigated the safety efficacy of neoadjuvant a combination nivolumab T-VEC regionally Methods: single arm phase II open-label (NCT04330430), 24 melanoma were included. Inclusion criteria RECIST 1.1 measurable...
Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is an oncolytic immunotherapy approved in Europe for the treatment of unresectable metastatic melanoma (stage IIIB–IVM1a). This study characterised real-world use T-VEC four European countries. Data on demographics, pattern, safety, and clinical effectiveness were examined a retrospective chart review patients with stage IIIB–IVM1a treated surgical (the Netherlands) medical (Austria, Germany, UK) oncology settings. Overall, 66 included...
9500 Background: Now that effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize a risk/benefit ratio is crucial. The new 8th Edition AJCC system for melanoma aims improve risk stratification. goal of this study was externally validate the prognostic discriminatory ability survival comparison 7th. Methods: Analysis prospective cohort patients treated Netherlands Cancer Institute 7/8th stage III between 2000 2016. Stage defined as regional lymph...
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1, intralesionally administered in patients with stage IIIB/C-IVM1a unresectable melanoma. When surgery not treatment option the head and neck region, T-VEC can be an elegant alternative to systemic immunotherapy. Ten metastatic melanoma region started monotherapy at Netherlands Cancer Institute. We collected data on response, adverse events (AEs), baseline characteristics. For response evaluation, we used clinical...
Abstract Background With the approval of adjuvant therapy for stage III melanoma, accurate staging is more important than ever. Sentinel node biopsy (SNB) an tool, yet presence capsular nevi (CN) can lead to a false‐positive diagnosis. Patients and Methods Retrospective analysis American Joint Committee on Cancer 7th edition IIIA melanoma patients who were treated at our institute between 2000 2015. SNB slides reviewed this study by expert pathologist. Results Of 159 eligible patients, 14...
Eczema in children is a chronic disabling condition. The impact of this condition on the lives families often underestimated by conventional physicians. As consequence parents may investigate complementary treatment options. Close monitoring paediatrician essential, considering that variety adverse effects can occur during use treatment. We present 5-year-old girl with eczema. She visited Chinese herbalist who prescribed an ointment. noticed eczema resolved fast, itching decreased and she...
Talimogene laherparepvec (T-VEC) is an oncolytic virus, approved for the treatment of stage IIIb-IVM1a melanoma with injectable disease (cutaneous, subcutaneous or lymphatic). It a modified herpes simplex virus type 1 that induces tumor-specific T-cell responses via reduction virally mediated suppression antigen presentation, stimulation viral pathogenicity and enhancement tumor-selective replication. Response rates up to 82.6% have been reported III disease. Acral lentiginous (ALM) rare...
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus type 1, which can be administered intralesionally in patients with stage IIIB/C-IVM1a (American Joint Committee of Cancer; AJCC 7th edition) unresectable melanoma. In the case disease recurrence, T-VEC re-introduced for same category patients. Five recurrent after prior achieved complete response (CR) recommenced treatment monotherapy at Netherlands Cancer Institute. We collected data on response, adverse events and baseline...
9593 Background: With the approval of adjuvant therapy for stage III melanoma, accurate staging in melanoma patients is important more than ever to prevent over- or undertreatment. Sentinel node biopsy (SNB) an tool, yet presence capsular nevi (CN) can lead a false positive diagnosis. We compared SNB and CN patient outcomes aimed evaluate cause discern diagnostic pitfalls their evaluation. Methods: Retrospective analysis AJCC 7th Edition IIIA (N1-2a, non-ulcerated primary tumor) who were...